Tenaya therapeutics reports third quarter 2024 financial results and provides business update

Data safety and monitoring board endorsed dose escalation and broadening of inclusion criteria in the mypeak tm -1 phase 1b/2 trial of tn-201 gene therapy

TNYA Ratings Summary

TNYA Quant Ranking